Major Late Toxicities After Conformal Radiotherapy for Nasopharyngeal Carcinoma-Patient- and Treatment-Related Risk Factors

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 4, 2009, Pages 1121-1128

  Lee, Anne W M ^a   Ng, W T ^a   Hung, W M ^a   Choi, C W ^a   Tung, Raymond ^b   Ling, Y H ^a   Cheng, Peter T C ^a   Yau, T K ^a   Chang, Amy T Y ^a   Leung, Samuel K C ^a   Lee, Michael C H ^a   Bentzen, Soren M ^c  

^a PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^b Hong Kong Cancer Fund ^*  (Hong Kong)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Concurrent chemotherapy; Late toxicity; Nasopharyngeal carcinoma; Radiation boost

Indexed keywords

CHEMOTHERAPY; DECISION MAKING; DOSIMETRY; MULTIVARIANT ANALYSIS; PESTICIDE EFFECTS; PLATINUM COMPOUNDS; RADIOTHERAPY;

CONCURRENT CHEMORADIOTHERAPY; CONCURRENT CHEMOTHERAPY; CONCURRENT CISPLATIN; CONFIDENCE INTERVALS; CONFORMAL RADIOTHERAPIES; CONVENTIONAL FRACTIONATIONS; DOSE ESCALATIONS; HAZARD RATIOS; LATE TOXICITY; MULTI-VARIATE ANALYSIS; NASOPHARYNGEAL CARCINOMA; OVERALL RATES; RADIATION DOSE; RELATED RISKS; SIGNIFICANT FACTORS; TEMPORAL LOBES; TOTAL DOSE;

TOXICITY;

CISPLATIN; FLUOROURACIL; GEMCITABINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN NECROSIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COCHLEA; CRANIAL NEUROPATHY; ENDOCRINE DISEASE; EYE INJURY; FEMALE; HAZARD RATIO; HEARING IMPAIRMENT; HUMAN; INNER EAR DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; PATIENT SELECTION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RETROSPECTIVE STUDY; RISK FACTOR; SOFT TISSUE DISEASE; SURVIVAL RATE; TRISMUS; TUMOR CLASSIFICATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR BURDEN; YOUNG ADULT;

EID: 61349183760     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.05.023     Document Type: Article

References (25)

1. Lee A.W.M., Perez C.A., Law C.K., et al. Nasopharynx. In: Halperin E.C., Perez C., and Brady L. (Eds). Principles and practice of radiation oncology. 5th ed. (2008), Lippincott Williams and Wilkins, Philadelphia 820-857
2. Al-Sarraf M., LeBlanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 16 (1998) 1310-1317
3. Baujat B., Audry H., Bourhis J., et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64 (2006) 47-56
4. Wee J., Tan E.H., and Tai B.C. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23 (2005) 6730-6738
5. Lee A.W.M., Lau W.H., Tung S.Y., et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23 (2005) 6966-6975
6. Teo P.M., Leung S.F., Lee W.Y., et al. Intracavitary brachytherapy significantly enhances local control of early T-stage nasopharyngeal carcinoma: The existence of a dose-tumor-control relationship above conventional tumoricidal dose. Int J Radiat Oncol Biol Phys 46 (2000) 445-458
7. Hara W., Loo B.W., Goffinet D.R., et al. Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 71 (2008) 393-400
8. Chen H., Tsai S.T., Wang M.S., et al. Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66 (2006) 1408-1414
9. Lee A.W.M., Sze W.M., Yau T.K., et al. Retrospective analysis on treating nasopharyngeal carcinoma with accelerated fractionation (6 fractions per week) in comparison with conventional fractionation (5 fractions per week): Report on 3-year tumor control and normal tissue toxicity. Radiother Oncol 58 (2001) 121-130
10. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. J Radiat Oncol Biol Phys 21 (1991) 109-122
11. Fleming I., Cooper J., Henson D., and American Joint Committee on Cancer. AJCC cancer staging manual. 5th ed. (1997), Lippincott-Raven, Philadelphia p. 31-39
12. Sobin L., Wittekind C., and International Union Against Cancer (UICC). TNM classification of malignant tumours. 5th ed. (1997), Wiley-Liss, New York
13. Lee A.W.M., Tung S.Y., Chan A.T., et al. Preliminary results of a randomized study (NPC-9902 trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66 (2006) 142-151
14. Lee A.W.M., Yau T.K., Wong D.H., et al. Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. Int J Radiat Oncol Biol Phys 63 (2005) 1331-1338
15. Yau T.K., Lee A.W.M., and Wong D.H.M. Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma. Head Neck 28 (2006) 880-887
16. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
17. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0. Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, December 12, 2003. Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed June 30, 2006.
18. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
19. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 35 (1977) 1-39
20. Cox D.R. Regression models and life tables. J R Stat Soc B 34 (1972) 187-220
21. Blakley B.W., and Myers S.F. Patterns of hearing loss resulting from cisplatinum therapy. Otolaryngol Head Neck Surg 109 (1993) 385-391
22. Low W.K., Toh S.T., Wee J., et al. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: A single, blinded, randomized study. J Clin Oncol 24 (2006) 1904-1909
23. Kwong D., Wei W., Sham J., et al. Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: A prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys 36 (1996) 281-289
24. Grau C., Moller K., Overgaard M., et al. Sensori-neural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 21 (1991) 723-728
25. Bhandare N., Antonelli P., Morris C., et al. Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys 67 (2007) 469-479